Response to Letter to the Editor re: "Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review": 'serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review'

F H van Bruggen, G B J Nijhuis, S U Zuidema, H J Luijendijk*

*Corresponding author voor dit werk

OnderzoeksoutputAcademicpeer review

1 Citaat (Scopus)
70 Downloads (Pure)
Originele taal-2English
Aantal pagina's2
TijdschriftExpert Review of Clinical Pharmacology
Volume14
Nummer van het tijdschrift2
DOI's
StatusPublished - 21-jan.-2021

Citeer dit